Equal IgG antibody response to pneumococcal vaccination in all stages of human immunodeficiency virus disease.
To evaluate the immunogenicity and safety of a 23-valent pneumococcal vaccine in human immunodeficiency virus (HIV)-seropositive patients, 80 men and 18 women received 1 dose of the vaccine (Pneumo 23; Pasteur Mérieux MSD, Brussels). The total IgG antibody response against all 23 Streptococcus pneumoniae capsular antigens was measured. Antibody levels were expressed in arbitrary units per microliter, referring to a standard curve. Geometric mean titers of the total IgG capsular antibodies on the day of vaccination and 30-45 days later were compared. The ratios of titers after and before vaccination in patients with > 500, 200-500, and < 200 CD4 lymphocytes/microL were 10, 10, and 12.6, respectively. Nonresponse (ratio < 4) occurred in 17% of patients and was unrelated to CD4 cell count. The vaccine was well tolerated; no serious side effects occurred. In 83% of the patients with HIV infection, the total antipneumococcal IgG level was higher after vaccination.
Vandenbruaene
M
M
Institute of Tropical Medicine, Antwerp, Belgium.
Colebunders
R
R
Mascart-Lemone
F
F
Haerden
Y
Y
Van Hove
D
D
Peeters
M
M
Goeman
J
J
Van Royen
P
P
Avonts
D
D
D000328:Adult; D000917:Antibody Formation; D001428:Bacterial Vaccines / Q000276:immunology*; D018791:CD4 Lymphocyte Count; D005260:Female; D015658:HIV Infections / Q000276:immunology*; D006679:HIV Seropositivity / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D022242:Pneumococcal Vaccines; D013296:Streptococcus pneumoniae / Q000276:immunology*
D001428:Bacterial Vaccines; D007074:Immunoglobulin G; D022242:Pneumococcal Vaccines